Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Yi, Hee ^a   Cho, Hee Jung ^a   Cho, Soo Min ^a   Lee, Dong Goo ^a   Abd El Aty, AM ^a,e   Yoon, So Jeong ^b   Bae, Gun Won ^b   Nho, Kwang ^b   Kim, Bokyung ^c   Lee, Chi Ho ^a   Kim, Jin Suk ^a   Bartlett, Michael G ^d   Shin, Ho Chul ^a  

^a Konkuk University   (South Korea)

^b SunBio Inc   (South Korea)

^c Konkuk University School of Medicine   (South Korea)

^d UNIVERSITY OF GEORGIA   (United States)

^e Cairo University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; MACROGOL; ANTINEOPLASTIC ANTIMETABOLITE; DRUG CARRIER; MACROGOL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RELEASE; GROWTH INHIBITION; HISTOPATHOLOGY; HYDROGEL; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG FORMULATION; DRUG IMPLANT; DRUG SCREENING; HUMAN; LUNG TUMOR; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; SOLUBILITY; SPRAGUE DAWLEY RAT; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; DRUG IMPLANTS; FLUOROURACIL; HUMANS; HYDROGELS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954361590     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-211     Document Type: Article

References (26)

1. Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E, Scheiner J. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957, 179:663-666. 10.1038/179663a0, 13418758.
2. Tanaka F, Fukuse T, Wada H, Fukushima M. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents. Curr Pharm Biotechnol 2000, 1:137-164. 10.2174/1389201003378979, 11467334.
3. Calabro-Jones PM, Byfield JE, Ward JF, Sharp TR. Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro. Cancer Res 1982, 42:4413-4420.
4. Drewinko B, Yang LY. Cellular basis for the inefficacy of 5-FU in human colon carcinoma. Cancer Treat Rep 1985, 69:1391-1398.
5. Link KH, Aigner KR, Peschau K, Warthona M, Schwemmle K, Danenberg PV. Concentration and time dependence of the toxicity of fluorinated pyrimidines to HT 29 colorectal carcinoma cells. Cancer Chemother Pharmacol 1988, 22:58-62. 10.1007/BF00254182, 2969305.
6. Weissleder R, Poss K, Wilkinson R, Zhou C, Bogdanov A. Quantitation of slow drug release from an implantable and degradable gentamicin conjugate by in vivo magnetic resonance imaging. Antimicrob Agents Chemother 1995, 39:839-845. 162639, 7785981.
7. Fabbri M, Iliopoulos D, Trapasso F, Aqeilan RI, Cimmino A, Zanesi N, Yendamuri S, Han SY, Amadori D, Huebner K, Croce CM. WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci USA 2005, 102:15611-15616. 10.1073/pnas.0505485102, 1266103, 16223882.
8. Jiang Y, Cui L, Yie TA, Rom WN, Cheng H, Tchou-Wong KM. Inhibition of anchorage-independent growth and lung metastasis of A549 lung carcinoma cells by IkappaBbeta. Oncogene 2001, 20:2254-2263. 10.1038/sj.onc.1204293, 11402320.
9. Kemeny N. Role of chemotherapy in the treatment of colorectal carcinoma. Semin Surg Oncol 1987, 3:190-214. 10.1002/ssu.2980030312, 3310182.
10. Drewinko B, Yang LY, Ho DH, Benvenuto J, Loo TL, Freireich EJ. Treatment of cultured human colon carcinoma cells with fluorinated pyrimidines. Cancer 1980, 45:1144-1158. 10.1002/1097-0142(19800315)45:5+<1144::AID-CNCR2820451319>3.0.CO;2-P, 6766799.
11. Murnane JP, Byfield JE, Ward JF, Calabro-Jones P. Effects of methylated xanthines on mammalian cells treated with bifunctional alkylating agents. Nature 1980, 285:326-329. 10.1038/285326a0, 7374784.
12. Roper PR, Drewinko B. Comparison of in vitro methods to determine drug-induced cell lethality. Cancer Res 1976, 36:2182-2188.
13. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. A comparison of 5-fluorouracil administered by slow infusion and rapid injection. Cancer Res 1972, 32:2717-2719.
14. Meta-analysis Group In Cancer Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998, 16:301-308. 9440757, Meta-analysis Group In Cancer.
15. Hansen RM, Ryan L, Anderson T, Krzywda B, Quebbeman E, Benson A, Haller DG, Tormey DC. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 1996, 88:668-674. 10.1093/jnci/88.10.668, 8627643.
16. Seifert P, Baker LH, Reed ML, Vaitkevicius VK. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975, 36:123-128. 10.1002/1097-0142(197507)36:1<123::AID-CNCR2820360108>3.0.CO;2-C, 1203840.
17. Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 2002, 95:1629-1636. 10.1002/cncr.10847, 12365009.
18. Lalloo A, Chao P, Hu P, Stein S, Sinko PJ. Pharmacokinetic and pharmacodynamic evaluation of a novel in situ forming poly(ethylene glycol)-based hydrogel for the controlled delivery of the camptothecins. J Control Release 2006, 112:333-342. 10.1016/j.jconrel.2006.03.002, 16650910.
19. Qiu B, Stefanos S, Ma J, Lalloo A, Perry BA, Leibowitz MJ, Sinko PJ, Stein S. A hydrogel prepared by in situ cross-linking of a thiol-containing poly(ethylene glycol)-based copolymer: a new biomaterial for protein drug delivery. Biomaterials 2003, 24:11-18. 10.1016/S0142-9612(02)00227-2, 12417173.
20. Greenblatt MS, Mangalik A, Ferguson J, Elias L. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha. Clin Cancer Res 1995, 1:615-620.
21. Gamelin E, Boisdron-Celle M. Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art. Crit Rev Oncol Hematol 1999, 30:71-79. 10.1016/S1040-8428(98)00036-5, 10439055.
22. Blanco MD, Garcia O, Gomez C, Sastre RL, Teijon JM. In-vivo drug delivery of 5-fluorouracil using poly(2-hydroxyethyl methacrylate-co-acrylamide) hydrogels. J Pharm Pharmacol 2000, 52:1319-1325. 10.1211/0022357001777469, 11186239.
23. Reitemeier RJ, Moertel CG. Comparison of rapid and slow intravenous administration of 5-fluorouracil in treating patients with advanced carcinoma of the large intestine. Cancer Chemother Rep 1962, 25:87-89.
24. Ansfield F, Klotz J, Nealon T, Ramirez G, Minton J, Hill G, Wilson W, Davis H, Cornell G. A phase III study comparing the clinical utility of four regimens of 5-fluorouracil: a preliminary report. Cancer 1977, 39:34-40. 10.1002/1097-0142(197701)39:1<34::AID-CNCR2820390107>3.0.CO;2-2, 318916.
25. Santini J, Milano G, Thyss A, Renee N, Viens P, Ayela P, Schneider M, Demard F. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 1989, 59:287-290. 2247002, 2930694.
26. Thyss A, Milano G, Renee N, Vallicioni J, Schneider M, Demard F. Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol 1986, 16:64-66. 10.1007/BF00255288, 3940221.